Harmony Biosciences Holdings (HRMY)
Harmony Biosciences Holdings, Inc. is a commercial-stage pharmaceutical company focused on therapies for rare neurological diseases in the United States. Its commercial product is WAKIX (pitolisant), a treatment for excessive daytime sleepiness in adult patients with narcolepsy. The company also has a pipeline that includes pitolisant in late-stage and mid-stage studies for indications such as Prader-Willi syndrome and myotonic dystrophy, along with additional formulations under development. Other programs in development include BP1.15205 and HBS-102, as well as ZYN-002 for Fragile X syndrome and 22q Deletion Syndrome, and several epilepsy-related candidates such as EPX-100, EPX-200, CBS105, and CBS104. Founded in 2017 and formerly known as Harmony Biosciences II, Inc., the company is headquartered in Plymouth Meeting, Pennsylvania.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-HRMY
|
$45.75
|
33.3% Upside
|
Undervalued
|
$44.91
|
30.8% Upside
|
Undervalued
|
Great
|
—
|
—
|
—
|
0.0%
|
August 11, 2026
|
13.7x
|
2.2x
|
2.2x
|
1.939 B
|
1.283 B
|
7.8%
|
89.4%
|
5.3
|
—
|
234.7%
|
